望月 眞弓 (モチヅキ マユミ)

Mochizuki, Mayumi

写真a

所属(所属キャンパス)

薬学部 薬学科 (芝共立)

職名

特任教授(有期)

 
 

著書 【 表示 / 非表示

  • 現代用語の基礎知識2019

    望月 眞弓, 自由国民社, 2018年11月

    担当範囲: 薬と社会

  • くすり創りの歴史

    内藤記念くすり博物館, 2018年08月

    担当範囲: 監修

  • 現代用語の基礎知識2018

    望月 眞弓, 自由国民社, 2017年11月

    担当範囲: 薬と社会

  • スタンダード薬学シリーズⅡ6 医療薬学Ⅶ 製剤化のサイエンス

    東京化学同人, 2017年10月

    担当範囲: 編集責任

  • スタンダード薬学シリーズⅡ6 医療薬学Ⅴ 薬物治療に役立つ情報

    東京化学同人, 2017年10月

    担当範囲: 編集責任

全件表示 >>

論文 【 表示 / 非表示

  • Long-term effect of NUDT15 R139C on hematologic indices in inflammatory bowel disease patients treated with thiopurine

    Akiyama S., Matsuoka K., Fukuda K., Hamada S., Shimizu M., Nanki K., Mizuno S., Kiyohara H., Arai M., Sugimoto S., Iwao Y., Ogata H., Hisamatsu T., Naganuma M., Motobayashi M., Suzuki K., Takenaka K., Fujii T., Saito E., Nagahori M., Ohtsuka K., Mochizuki M., Watanabe M., Hashiguchi M., Kanai T.

    Journal of Gastroenterology and Hepatology (Australia) (Journal of Gastroenterology and Hepatology (Australia))  34 ( 10 ) 1751 - 1757 2019年10月

    ISSN  08159319

     概要を見る

    © 2019 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd Background and Aim: A missense variant of the nucleoside diphosphate-linked moiety X-type motif 15 (NUDT15) gene (R139C) predisposes Asian patients with inflammatory bowel disease (IBD) to thiopurine-induced leukopenia. This study evaluates the long-term effect of NUDT15 R139C heterozygosity on hematological parameters during thiopurine administration. Methods: We enrolled 83 Japanese IBD patients who were on anti-tumor necrosis factor-α agents and had used thiopurine. NUDT15 R139C was genotyped by polymerase chain reaction. We retrospectively reviewed patient clinical charts to collect data on white blood cell (WBC) count, mean corpuscular volume (MCV), hemoglobin, and platelet count during the 24 months following thiopurine initiation. Results: The included patients had either Crohn's disease (54; 65.1%) or ulcerative colitis (29; 34.9%). Genotyping of NUDT15 R139C identified 62 patients (74.7%) of genotype C/C and 21 (25.3%) of genotype C/T. The median dose of thiopurine was lower in the C/T group than in the C/C group after starting thiopurine. At 6 months, the mean WBC count of the C/T group became significantly lower than that of the C/C group (P = 0.008) and remained lower through the 24 months. The C/T group developed grade 2–4 leukopenia by 6 months, which persisted through 12–24 months. The mean MCV in the C/T group became higher than that of the C/C group after 3 months. Conclusions: NUDT15 R139C heterozygosity affected the WBC count and MCV for 24 months after thiopurine administration. Our results indicate that careful monitoring of leukopenia and dose adjustment are necessary throughout treatment in IBD patients heterozygous for the NUDT15 R139C.

  • Positive predictive value of ICD-10 codes for acute myocardial infarction in Japan: A validation study at a single center

    Ando T., Ooba N., Mochizuki M., Koide D., Kimura K., Lee S., Setoguchi S., Kubota K.

    BMC Health Services Research (BMC Health Services Research)  18 ( 1 )  2018年11月

     概要を見る

    © 2018 The Author(s). Background: In Japan, several large healthcare databases have become available for research since the early 2000's. However, validation studies to examine the accuracy of these databases remain scarce. We conducted a validation study in order to estimate the positive predictive value (PPV) of local or ICD-10 codes for acute myocardial infarction (AMI) in Japanese claims. In particular, we examined whether the PPV differs between claims in the Diagnosis Procedure Combination case mix scheme (DPC claims) and in non-DPC claims. Methods: We selected a random sample of 200 patients from all patients hospitalized at a large tertiary-care university hospital between January 1, 2009 and December 31, 2011 who had an inpatient claim assigned a local or ICD-10 code for AMI. We used a standardized data abstraction form to collect the relevant information from an electronic medical records system. Abstracted information was then categorized by a single cardiologist as being either definite or not having AMI. Results: In a random sample of 200 patients, the average age was 67.7 years and the proportion of males was 78.0%. The PPV of the local or ICD-10 code for AMI was 82.5% in this sample of 200 patients. Further, of 178 patients who had an ICD-10 code for AMI based on any of the 7 types of condition codes in the DPC claims, the PPV was 89.3%, whereas of the 161 patients who had an ICD-10 code for AMI based on any of 3 major types of condition codes in the DPC claims, the PPV was 93.8%. Conclusion: The PPV of the local or ICD-10 code for AMI was high for inpatient claims in Japan. The PPV was even higher for the ICD-10 code for AMI for those patients who received AMI care through the DPC case mix scheme. The current study was conducted in a single center, suggesting that a multi-center study involving different types of hospitals is needed in the future. The accuracy of condition codes for DPC claims in Japan may also be worth examining for conditions other than AMI such as stroke.

  • Factors predicting the therapeutic response to infliximab during maintenance therapy in Japanese patients with Crohn's disease

    Matsuoka, Katsuyoshi, Hamada, Shunsuke, Shimizu, Mikiko, Nanki, Kosaku, Mizuno, Shinta, Kiyohara, Hiroki, Arai, Mari, Sugimoto, Shinya, Iwao, Yasushi, Ogata, Haruhiko, Hisamatsu, Tadakazu, Naganuma, Makoto, Kanai, Takanori, Mochizuki, Mayumi, Hashiguchi, Masayuki

    PLOS ONE 13 ( 10 )  2018年10月

    研究論文(学術雑誌), 共著, 査読有り,  ISSN  1932-6203

  • Factors Predicting the Therapeutic Response to Methotrexate in Japanese Patients with Rheumatoid Arthritis: A Hospital-Based Cohort Study

    Hakamata, Jun, Kaneko, Yuko, Shimizu, Mikiko, Yamaoka, Kunihiro, Maruyama, Junya, Takeuchi, Tsutomu, Mochizuki, Mayumi, Hashiguchi, Masayuki

    BIOLOGICAL & PHARMACEUTICAL BULLETIN 41 ( 9 ) 1414 - 1422 2018年09月

    研究論文(学術雑誌), 共著, 査読有り,  ISSN  0918-6158

  • Extraction and standardization of patient complaints from electronic medication histories for pharmacovigilance: Natural language processing analysis in Japanese

    Usui M., Aramaki E., Iwao T., Wakamiya S., Sakamoto T., Mochizuki M.

    Journal of Medical Internet Research (Journal of Medical Internet Research)  20 ( 9 )  2018年09月

     概要を見る

    © Misa Usui, Eiji Aramaki, Tomohide Iwao, Shoko Wakamiya, Tohru Sakamoto, Mayumi Mochizuki. Originally published in JMIR Medical Informatics (http://medinform.jmir.org), 27.09.2018. This is an open-access article distributed under the terms of the Creative Commons Attribution License. Background: Despite the growing number of studies using natural language processing for pharmacovigilance, there are few reports on manipulating free text patient information in Japanese. Objective: This study aimed to establish a method of extracting and standardizing patient complaints from electronic medication histories accumulated in a Japanese community pharmacy for the detection of possible adverse drug event (ADE) signals. Methods: Subjective information included in electronic medication history data provided by a Japanese pharmacy operating in Hiroshima, Japan from September 1, 2015 to August 31, 2016, was used as patients' complaints. We formulated search rules based on morphological analysis and daily (nonmedical) speech and developed a system that automatically executes the search rules and annotates free text data with International Classification of Diseases, Tenth Revision (ICD-10) codes. The performance of the system was evaluated through comparisons with data manually annotated by health care workers for a data set of 5000 complaints. Results: Of 5000 complaints, the system annotated 2236 complaints with ICD-10 codes, whereas health care workers annotated 2348 statements. There was a match in the annotation of 1480 complaints between the system and manual work. System performance was .66 regarding precision, .63 in recall, and .65 for the F-measure. Conclusions: Our results suggest that the system may be helpful in extracting and standardizing patients' speech related to symptoms from massive amounts of free text data, replacing manual work. After improving the extraction accuracy, we expect to utilize this system to detect signals of possible ADEs from patients' complaints in the future.

全件表示 >>

KOARA(リポジトリ)収録論文等 【 表示 / 非表示

総説・解説等 【 表示 / 非表示

  • The report: Promotion of social contributions of research on clinical pharmacy and pharmaceutical sciences

    Mochizuki M.

    Yakugaku Zasshi (Yakugaku Zasshi)  139 ( 3 ) 393 - 394 2019年

    ISSN  00316903

     概要を見る

    © 2019 The Pharmaceutical Society of Japan. The Science Council of Japan issued ``The report: Promotion of Social Contributions of Research on Clinical Pharmacy and Pharmaceutical Sciences'' on September 29, 2017. This report was prepared based on the analysis of current situation of the four-year doctoral course in the graduate school of pharmacy and the contents of the symposium of 137th annual meeting of the Pharmaceutical Society of Japan (PSJ), ``Pharmaceutical Sciences in the Future: The Bridge Linking between Basic and Clinical Research''. The goal of the 4-year doctoral program is to nurture the phar-macist-scientist who has both researcher mind and professionalism as a clinical pharmacist. Research on clinical pharmacy and pharmaceutical sciences is a core research area of the 4-year doctoral course, therefore its promotion is an important issue for the faculty of pharmacy. ``Research on clinical pharmacy and pharmaceutical sciences'' has to be based on various subjects and needs of the clinical site and be conducted not only at the clinical setting but also in universities, industries, research institutions and so on. Finally, the results have to be fed back to medical care and contribute to society. In this symposium, several representatives from various academic societies and one research institution which have important functions for academic interchanges, will give presentations on issues and initiatives for promoting research on clinical pharmacy and pharmaceutical sciences.

  • Sustainableな薬学図書館であるために

    望月 眞弓

    薬学図書館 63 ( 4 ) 205 - 210 2018年10月

    総説・解説(学術雑誌), 単著

  • 【老年医学(上)-基礎・臨床研究の最新動向-】 高齢患者へのアプローチ 高齢者の薬物治療 Potentially Inappropriate Medicine(PIM)

    望月 眞弓, 青森 達

    日本臨床 (日本臨床)  76 ( 増刊5 ) 347 - 353 2018年06月

    総説・解説(商業誌、新聞、ウェブメディア), 共著

  • 【私の処方2018】 添付文書の読み方

    望月 眞弓

    小児科臨床 (日本小児医事出版社)  71 ( 5 ) 611 - 620 2018年05月

    総説・解説(商業誌、新聞、ウェブメディア), 単著

  • 薬剤師inプライマリ・ケア 大学病院における薬剤師の活躍

    山口 雅也, 望月 眞弓

    プライマリ・ケア 3 ( 1 ) 57 - 59 2018年03月

    総説・解説(学術雑誌), 共著

全件表示 >>

研究発表 【 表示 / 非表示

  • 医薬品安全性情報の自発報告の位置づけ 患者からの副作用報告システムの構築の経験から 経緯、現状と課題

    橋口正行、望月眞弓

    日本薬剤疫学会学術総会第24回 Page34-35(2018.10) (仙台) , 2018年10月, シンポジウム・ワークショップ パネル(指名), 日本薬剤疫学会

  • 医療用医薬品添付文書の古くて新しい話

    望月 眞弓

    第38回日本臨床薬理学会 (京都) , 2018年07月, 公開講演,セミナー,チュートリアル,講習,講義等, 日本臨床薬理学会

  • 日本病院薬剤師会策定「医薬品情報業務の進め方2018」と私のDI業務 日本病院薬剤師会策定「医薬品情報業務の進め方2018」の概要

    望月 眞弓

    第21回日本医薬品情報学会総会・学術大会 (鈴鹿) , 2018年06月, シンポジウム・ワークショップ パネル(公募), 日本医薬品情報学会

  • プラセボ効果の個体間変動要因の検討のためのスタディプロトコール

    横山 由佳, 神成 はるか, 井澤 美苗, 早川 智久, 青森 達, 望月 眞弓

    第21回日本医薬品情報学会総会・学術大会 (鈴鹿) , 2018年06月, ポスター(一般), 日本医薬品情報学会

  • 製薬会社によるデジタル化された医薬品情報の提供・利活用に関する調査

    中田 英夫, 石川 春樹, 木村 元範, 我妻 秀和, 村松 博, 望月 眞弓

    第21回日本医薬品情報学会総会・学術大会 (鈴鹿) , 2018年06月, ポスター(一般), 日本医薬品情報学会

全件表示 >>

競争的資金等の研究課題 【 表示 / 非表示

  • 工学的発想と臨床心理学的発想に基づく一般用医薬品添付文書の開発

    2015年04月
    -
    2018年03月

    文部科学省・日本学術振興会, 科学研究費助成事業, 望月 眞弓, 基盤研究(C), 補助金,  代表

受賞 【 表示 / 非表示

  • 福澤賞

    望月眞弓, 2018年11月, 慶應義塾, 医薬品情報学に関する先駆的な教育・研究と学術への貢献

    受賞区分: 塾内表彰等,  受賞国: 日本

  • 日本医療薬学会功績賞

    2016年09月, 日本医療薬学会

    受賞区分: 国内学会・会議・シンポジウム等の賞,  受賞国: 日本

  • 永井記念国際女性科学者賞

    2016年06月, 日本薬剤学会

    受賞区分: 国内外の国際的学術賞

  • 日本医薬品情報学会論文賞

    橋口正行、金子梨沙、保坂藍、植田恵子、小寺典子、中村眞弓、榊原幹夫、黒川達夫、望月眞弓., 2013年08月, 日本医薬品情報学会, 一般用医薬品の添付文書理解度調査法の開発、ー理解度への影響因子の検討ー.

  • 私立薬科大学協会教育賞

    望月眞弓, 2012年03月, 私立薬科大学協会

    受賞区分: その他の賞,  受賞国: 日本

全件表示 >>

 

担当授業科目 【 表示 / 非表示

  • 課題研究(病院薬学)

    2019年度

  • 演習(病院薬学)

    2019年度

  • 医療系薬学特論Ⅰ

    2019年度